Hoth Therapeutics Shares Major Pipeline Updates: What’s Moving, What’s Next

Hoth Therapeutics has released a detailed update on its clinical and preclinical programs. The company is advancing four key assets, HT-001, HT-KIT, HT-ALZ, and its new GDNF-based metabolic program, while strengthening its IP portfolio and expanding research partnerships.

HT-001: Phase 2 Trial Progresses With Strong Safety Signals

HT-001 targets EGFR-inhibitor–associated rash, a common and challenging side effect in cancer care.

Recent progress:

• No dose-limiting toxicities reported so far.
• Clear improvement trends in rash severity and itching.
• Rising engagement from clinical sites with positive investigator feedback.
• More Phase 2 data expected in the coming months.

HT-KIT: Orphan Drug Program Edges Toward IND Submission

HT-KIT is designed for mastocytosis and other mast-cell–driven conditions.

Key accomplishments:

• Already granted FDA Orphan Drug Designation.
• Preclinical data shows potent KIT inhibition and strong mast-cell suppression.
• IND-enabling toxicology work nearing completion.
• Manufacturing scale-up and analytical testing underway.
• IND submission targeted for 2026, followed by first-in-human studies.

HT-ALZ: Advancing Through GLP Studies for Alzheimer’s Disease

HT-ALZ continues to move forward with supportive safety and PK data.

Latest developments:

• GLP studies underway with promising PK and biodistribution results.
• Early CNS-penetration modeling appears favorable.
• Regulatory-focused data package expected to mature in 2026.

New GDNF-Based Metabolic Program Gains Momentum

Hoth’s newest program uses GDNF to target obesity, liver fat accumulation, and broader metabolic dysfunction, areas with massive global demand.

Recent milestones:

• Study preparations initiated with the Atlanta VA Medical Center.
• Mouse procurement completed; high-fat-diet model now active.
• Aim 1 officially underway with initial results expected in 2026.
• Program supported by strong academic collaboration and new IP filings.

Strengthening IP and Expanding Partnerships

Hoth continues to build a robust IP portfolio across all programs, including:

• HT-001 mechanisms for dermatology and oncology care.
• HT-KIT formulations and manufacturing processes.
• HT-ALZ delivery technologies and CNS data.
• GDNF applications in weight-loss and hepatic health.

The company also maintains active partnerships with the Atlanta VA, neuroscience groups, and AI-driven discovery teams.

Key Milestones to Watch

• New Phase 2 data from the CLEER-001 trial for HT-001.
• Completion of HT-KIT toxicology studies and IND filing.
• Expanded GLP and PK readouts for HT-ALZ.
• Early findings from the GDNF metabolic program.

Leadership View

According to CEO Robb Knie, the pipeline is “more focused and better positioned than ever.” Each program is advancing toward meaningful clinical or preclinical inflection points.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!